Nialamide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nialamide
Nialamide.svg
Systematic (IUPAC) name
N-benzyl-3-(N'-(pyridine-4-carbonyl)hydrazino)propanamide
Clinical data
AHFS/Drugs.com International Drug Names
Legal status Prescription Only (S4) (AU)
Routes Oral
Identifiers
CAS number 51-12-7 YesY
ATC code N06AF02
PubChem CID 4472
DrugBank DB04820
ChemSpider 4317 YesY
UNII T2Q0RYM725 YesY
KEGG D07337 YesY
Chemical data
Formula C16H18N4O2 
Mol. mass 298.34 g/mol
 YesY (what is this?)  (verify)

Nialamide (Niamid) is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class used as an antidepressant and anxiolytic. Along with phenelzine and isocarboxazid, it is one of the few hydrazine MAOIs still in clinical use.[citation needed]


Investigational uses[edit]

Nialamide is sometimes used in the treatment of trigeminal neuralgia, generalized anxiety disorder and social phobia. It has also been studied for alcoholism,[1] dermatomally distributed vitiligo,[2] irregular menstruation,[3] angina,[4] cerebrovascular disorders,[5] and the prevention of streptomycin-induced deafness.[6]

Side effects[edit]

Side effects on central nervous system include euphoria, psychomotor agitation, insomnia, anxiety, headache, vertigo, tremor, hyperreflexia, manic state, or turning a depression into mania in bipolar disorder. Other side effects are arterial and orthostatic hypotensions, arterial hypertension, palpitations, hyperhidrosis, dry mouth, nausea, vomiting, epigastric pain, constipation, vision problems, retrobulbar optic neuritis, polyneuritis, weight gain, acute cardiac insufficiency, tachycardia, peripheral neuropathy, jaundice, hepatomegaly, hyperbilirubinemia, urinary retention, elevated transaminases, cutaneous eruptions, impotence, and delayed ejaculation. Dangerous side effects are drug-induced hepatitis and hepatocellular insufficiency. As with all MAOIs, nialamide is contraindicated in patients using SSRIs, SSRAs, and serotonin agonists.

See also[edit]

References[edit]

  1. ^ Bobrov AE, Shurygin AN, Krasil'nikov SB (1991). "[Effectiveness of combined use of monoamine oxidase inhibitors and psychotherapy in the treatment of chronic alcoholism]". Zhurnal Nevropatologii i Psikhiatrii Imeni SS Korsakova. 91 (2): 79–83. PMID 1647635. 
  2. ^ Koga M (1977). "Vitiligo: a new classification and therapy". British Journal of Dermatology 97 (3): 255–61. doi:10.1111/j.1365-2133.1977.tb15180.x. PMID 921895. 
  3. ^ Gautray JP, Jolivet A (1976). "[Neuroendocrine investigation and therapy of the menstrual cycle disorders (author's transl)(proceedings)]". Annales d'endocrinologie 37 (4): 293–4. PMID 1022189. 
  4. ^ Barats SS, Oranskii IE, Kartashova DI, Gorovater EN (1976). "[Comparative clinico-physiological study of the effect of several MAO inhibitors in stenocardia]". Kardiologiia 16 (3): 138–40. PMID 1021625. 
  5. ^ Mirzoian RS (1975). "[Prevention of cerebrovascular disorders with adrenergic substances]". Biulleten' Eksperimental'noi Biologii i Meditsiny 80 (11): 50–3. PMID 1218262. 
  6. ^ Semczuk B, Klonowski S, Golabek W (1974). "The protective effect of niamid on hearing in patients treated with large doses of streptomycin". Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina 29 (1): 193–7. PMID 4467804.